A Phase II Randomised, Double-blind, Placebo-controlled, Incomplete Crossover Trial With 4-week Treatment Periods to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution (Doses of 1.25 microg, 2.5 microg and 5 microg) Delivered Via Respimat Inhaler Once Daily in the Evening in Adolescents (12 to 17 Yrs Old) With Moderate Persistent Asthma.

Trial Profile

A Phase II Randomised, Double-blind, Placebo-controlled, Incomplete Crossover Trial With 4-week Treatment Periods to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution (Doses of 1.25 microg, 2.5 microg and 5 microg) Delivered Via Respimat Inhaler Once Daily in the Evening in Adolescents (12 to 17 Yrs Old) With Moderate Persistent Asthma.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 May 2016

At a glance

  • Drugs Tiotropium bromide (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 18 May 2016 Results of five trials (n=1397) presented at the 112th International Conference of the American Thoracic Society
    • 23 May 2012 Results presented at the 108th International Conference of the American Thoracic Society.
    • 22 May 2012 Results published in a Boehringer Ingelheim media release and presented at the 2012 Annual Meeting of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top